Stock still trading wayy below cash . If the Phase 3 results are similar like those from Phase 2 then we will have here an 10 bagger easily .GL



Market Cap: $53 Million

Cash: $68 Million

Price: 0.59



from tuesdays conference call :

As you know we had, albeit small each of them, but two successful Phase 2 studies behind zoptarelin doxorubicin. In addition to endometrial cancer, we had one in ovarian cancer. Both trials, although conducted separately, demonstrated very favorable side effect profile, no reported cardio toxicity and they both also indicated overall survival of the 15 months compared to standard doxorubicin, the literature as you may recall is around seven to nine months, so it is very promising and we have a full plan of lifecycle management behind this compound based upon success in our current program in endometrial cancer we would then proceed into further indication development and working to really develop this molecule for applications making it a very important tool in the hands of oncologists and for their patients in a number of barriers in oncology


----

Results from a PII study in 43 patients with LHRH-positive advanced endometrial cancer were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Patients received AEZS-108 267 mg/m2 by IV infusion over 2 hours, with retreatment every 3 weeks, for up to 6 courses. The primary endpoint was response rate based on RECIST criteria. 2 patients had a complete response (CR; 5.1%), 10 a partial response (PR; 25.6%), and 17 stable disease (SD; 43.6%), giving an Overall Response Rate (ORR = CR+PR) of 30.8 % and a Clinical Benefit Rate (CBR = CR+PR+SD) of 74.4%; responses were seen in patients who had prior platinum/taxane chemotherapy. Median time to progression and overall survival were 7 months and 14.3 months, respectively .